Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro

References

• AbrahamCChoJHInflammatory bowel diseaseN Engl J Med2009361212066207819923578
   PubMed Web of Science ®Google Scholar
• ClickBBinionDGAndersonAMPredicting costs of care for patients with inflammatory bowel diseasesClin Gastroenterol Hepatol201715339339527923719
   PubMed Web of Science ®Google Scholar
• OttCSchölmerichJExtraintestinal manifestations and complications in IBDNat Rev Gastroenterol Hepatol2013101058559523835489
   PubMed Web of Science ®Google Scholar
• FakhouryMNegruljRMooranianAAl-SalamiHInflammatory bowel disease: clinical aspects and treatmentsJ Inflamm Res2014711312025075198
   PubMedGoogle Scholar
• AnanthakrishnanANDonaldsonTLaschKYajnikVManagement of inflammatory bowel disease in the elderly patient: challenges and opportunitiesInflamm Bowel Dis201723688289328375885
   PubMed Web of Science ®Google Scholar
• XavierRJPodolskyDKUnravelling the pathogenesis of inflammatory bowel diseaseNature2007448715242743417653185
   PubMed Web of Science ®Google Scholar
• PapadakisKATarganSRRole of cytokines in the pathogenesis of inflammatory bowel diseaseAnnu Rev Med200051128929810774465
   PubMed Web of Science ®Google Scholar
• NairDGMillerKGLourenssenSRBlennerhassettMGInflammatory cytokines promote growth of intestinal smooth muscle cells by induced expression of PDGF-RβJ Cell Mol Med201418344445424417820
   PubMed Web of Science ®Google Scholar
• NairDGHanTYLourenssenSBlennerhassettMGProliferation modulates intestinal smooth muscle phenotype in vitro and in colitis in vivoAm J Physiol Gastrointest Liver Physiol20113005G903G91321311027
   PubMed Web of Science ®Google Scholar
• VreesMDPricoloVEPotentiFMCaoWAbnormal motility in patients with ulcerative colitis: the role of inflammatory cytokinesArch Surg20021374439445 discussion 445–44611926949
   PubMedGoogle Scholar
• MeierJJGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitusNat Rev Endocrinol201281272874222945360
   PubMed Web of Science ®Google Scholar
• ErvinnaNMitaTYasunariEAnagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient miceEndocrinology201315431260127023337530
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFFranzettiIGEffects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapyCan J Physiol Pharmacol201391972473223984793
   PubMed Web of Science ®Google Scholar
• ChristensenMKnopFKOnce-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide?Curr Diab Rep201010212413220425571
   PubMed Web of Science ®Google Scholar
• BanKNoyan-AshrafMHHoeferJBolzSSDruckerDJHusainMCardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathwaysCirculation2008117182340235018427132
   PubMed Web of Science ®Google Scholar
• MayATIdentification of Expression and Function of the Glucagon-like Peptide-1 Receptor in Gastrointestinal Smooth Muscle [master’s thesis]Richmond, VAVCU University Archives, Virginia Commonwealth University2017
   Google Scholar
• AnbazhaganANThaqiMPriyamvadaSGLP-1 nanomedicine alleviates gut inflammationNanomedicine201713265966527553076
   PubMed Web of Science ®Google Scholar
• KahlesFMeyerCMöllmannJGLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose loweringDiabetes201463103221322924947356
   PubMed Web of Science ®Google Scholar
• LebherzCSchlieperGMöllmannJGLP-1 levels predict mortality in patients with critical illness as well as end-stage renal diseaseAm J Med20171307833841.e328366423
   PubMed Web of Science ®Google Scholar
• LebherzCKahlesFPiotrowskiKInterleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolismCardiovasc Diabetol20161512126842302
   PubMed Web of Science ®Google Scholar
• MimuraSAndoTIshiguroKDipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitisScand J Gastroenterol201348101152115924047394
   PubMed Web of Science ®Google Scholar
• SakanakaTInoueTYorifujiNThe effects of a TGR5 agonist and a dipeptidyl peptidase IV inhibitor on dextran sulfate sodium-induced colitis in miceJ Gastroenterol Hepatol201530Suppl 1606525827806
   PubMed Web of Science ®Google Scholar
• CamilleriMVazquez-RoqueMIturrinoJEffect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndromeAm J Physiol Gastrointest Liver Physiol20123031G120G12822517769
   PubMed Web of Science ®Google Scholar
• ClayburghDRShenLTurnerJRA porous defense: the leaky epithelial barrier in intestinal diseaseLab Invest200484328229114767487
   PubMed Web of Science ®Google Scholar
• BerkesJViswanathanVKSavkovicSDHechtGIntestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammationGut200352343945112584232
   PubMed Web of Science ®Google Scholar
• SnapeWJrWilliamsRHymanPEDefect in colonic smooth muscle contraction in patients with ulcerative colitisAm J Physiol19912616 Pt 1G987G9911685073
   PubMed Web of Science ®Google Scholar
• SeveriCSferraRSciroccoAContribution of Intestinal Smooth Muscle to Crohn’s Disease FibrogenesisEur J Histochem2014584245725578979
   PubMed Web of Science ®Google Scholar
• ShiXZSarnaSKTranscriptional regulation of inflammatory mediators secreted by human colonic circular smooth muscle cellsAm J Physiol Gastrointest Liver Physiol20052892G274G28415790759
   PubMed Web of Science ®Google Scholar
• SalinthoneSSingerCAGerthofferWTInflammatory gene expression by human colonic smooth muscle cellsAm J Physiol Gastrointest Liver Physiol20042873G627G63715117678
   PubMed Web of Science ®Google Scholar
• BaggioLLDruckerDJBiology of incretins: GLP-1 and GIPGastroenterology200713262131215717498508
   PubMed Web of Science ®Google Scholar
• LeeYSJunHSAnti-inflammatory effects of GLP-1-based therapies beyond glucose controlMediators Inflamm20162016309464227110066
   PubMed Web of Science ®Google Scholar
• ChaudhuriAGhanimHVoraMExenatide exerts a potent anti-inflammatory effectJ Clin Endocrinol Metab201297119820722013105
   PubMed Web of Science ®Google Scholar
• ZhuTWuXLZhangWXiaoMGlucagon like peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-κB (NF-κB) signaling pathway in miceInt J Mol Sci2015169201952021126343632
   PubMed Web of Science ®Google Scholar
• RizzoGPuglieseDArmuzziACocoCAnti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?World J Gastroenterol201420174839484524803795
   PubMed Web of Science ®Google Scholar
• BradleyJRTNF-mediated inflammatory diseaseJ Pathol2008214214916018161752
   PubMed Web of Science ®Google Scholar
• DionneSD’AgataIDHiscottJVanounouTSeidmanEGColonic explant production of IL-1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD)Clin Exp Immunol199811234354429649212
   PubMed Web of Science ®Google Scholar
• CominelliFPizarroTTInterleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel diseaseAliment PharmacolTher199610Suppl 24953 discussion 54
   Web of Science ®Google Scholar
• NeurathMFCytokines in inflammatory bowel diseaseNat Rev Immunol201414532934224751956
   PubMed Web of Science ®Google Scholar
• MarshallDCameronJLightwoodDLawsonADBlockade of colony stimulating factor-1 (CSF-I) leads to inhibition of DSS-induced colitisInflamm Bowel Dis200713221922417206685
   PubMed Web of Science ®Google Scholar
• GhiaJEGaleazziFFordDCHogaboamCMVallanceBACollinsSRole of M-CSF-dependent macrophages in colitis is driven by the nature of the inflammatory stimulusAm J Physiol Gastrointest Liver Physiol20082943G770G77718202111
   PubMed Web of Science ®Google Scholar
• WernerLGuzner-GurHDotanIInvolvement of CXCR4/CXCR7/CXCL12 interactions in inflammatory bowel diseaseTheranostics201331404623382785
   PubMed Web of Science ®Google Scholar
• DaneseSGasbarriniAChemokines in inflammatory bowel diseaseJ Clin Pathol200558101025102716189145
   PubMed Web of Science ®Google Scholar
• TurnerMDNedjaiBHurstTPenningtonDJCytokines and chemokines: at the crossroads of cell signalling and inflammatory diseaseBiochim Biophys Acta20141843112563258224892271
   PubMed Web of Science ®Google Scholar
• MazzucchelliLHauserCZgraggenKDifferential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel diseaseJ Pathol199617822012068683390
   PubMed Web of Science ®Google Scholar
• ScheerensHHesselEde Waal-MalefytRLeachMWRennickDCharacterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL-10-/- mice and Rag-2-/-mice reconstituted with CD4+CD45RBhigh T cellsEur J Immunol20013151465147411465103
   PubMed Web of Science ®Google Scholar
• XiaXMWangFYZhouJHuKFLiSWZouBBCXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitisPLoS One2011611e2728222073304
   PubMed Web of Science ®Google Scholar
• YustaBBaggioLLKoehlerJGLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1RDiabetes20156472537254925735732
   PubMed Web of Science ®Google Scholar
• NagayamaKKyotaniYZhaoJExendin-4 prevents vascular smooth muscle cell proliferation and migration by angiotensin II via the inhibition of ERK1/2 and JNK signaling pathwaysPloS One2015109e013796026379274
   PubMed Web of Science ®Google Scholar
• MooreAWilloughbyDThe role of cAMP regulation in controlling inflammationClin Exp Immunol199510133873897664483
   PubMed Web of Science ®Google Scholar
• SpadacciniMD’AlessioSPeyrin-BirouletLDaneseSPDE4 inhibition and inflammatory bowel disease: a novel therapeutic avenueInt J Mol Sci2017186 pii: E1276
   Web of Science ®Google Scholar
• MinguetSHuberMRosenkranzLSchamelWWRethMBrummerTAdenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptorsEur J Immunol2005351314115580656
   PubMed Web of Science ®Google Scholar
• DaiYMehtaJLChenMGlucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activationCardiovasc Drugs Ther201327537138023657563
   PubMed Web of Science ®Google Scholar
• KoderaRShikataKKataokaHUGlucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetesDiabetologia201154496597821253697
   PubMed Web of Science ®Google Scholar
• VermillionDLHuizingaJDRiddellRHCollinsSMAltered small intestinal smooth muscle function in Crohn’s diseaseGastroenterology19931046169216998500728
   PubMed Web of Science ®Google Scholar
• AmatoABaldassanoSLiottaRSerioRMulèFExogenous glucagon-like peptide 1 reduces contractions in human colon circular muscleJ Endocrinol20142211293724443715
   PubMed Web of Science ®Google Scholar